The Institute for Clinical and Economic Review, ICER, a nonprofit that has become a central player in the debate over drug prices by doing its own analyses of what medicines are worth, is partnering with Aetion, a startup that analyzes insurance claims and other data mostly for pharmaceutical companies.
The partnership will try to use Aetion’s tools to help ICER make better decisions in creating its cost-effectiveness analyses of new medicines.
About the Author Reprints
